JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Francesco Onorati
Antonino S. Rubino
Giuseppe Santarpino
Attilio Renzulli
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Onorati, F.
Right arrow Articles by Renzulli, A.
PubMed
Right arrow Articles by Onorati, F.
Right arrow Articles by Renzulli, A.
Related Collections
Right arrow Cardiac - other
Right arrow Congestive Heart Failure
Right arrow Coronary disease
Right arrow Valve disease

J Thorac Cardiovasc Surg 2009;138:654-662
© 2009 The American Association for Thoracic Surgery

Acquired Cardiovascular Disease

Midterm clinical and echocardiographic results and predictors of mitral regurgitation recurrence following restrictive annuloplasty for ischemic cardiomyopathy

Francesco Onorati, MDa,*, Antonino S. Rubino, MDa, Domenico Marturano, MDa, Eugenia Pasceri, MDb, Giuseppe Santarpino, MDa, Stefania Zinzi, MDb, Giuseppina Mascaro, MDb, Attilio Renzulli, MD, PhD, FECTSa

a Cardiac Surgery Unit, Magna Graecia University of Catanzaro, Catanzaro, Italy
b Cardiology Unit, Magna Graecia University of Catanzaro, Catanzaro, Italy

Received for publication October 16, 2008; revisions received December 18, 2008; accepted for publication January 24, 2009.

* Address for reprints: Francesco Onorati, MD, Viale dei Pini, 28, 80131 Napoli, Italy. (Email: frankono{at}libero.it).

Objective: Although mitral restrictive annuloplasty plus coronary artery bypass grafting are considered the best therapeutic strategies for ischemic cardiomyopathy with chronic mitral regurgitation, some recurrences are still reported. We evaluated predictors for late recurrence of ischemic cardiomyopathy with chronic mitral regurgitation.

Methods: Hospital outcome and serial clinical and echocardiographic (preoperative, discharge, 6 months, end of follow-up) follow-up assessments were recorded for 82 consecutive patients with ischemic cardiomyopathy with chronic mitral regurgitation having coronary artery bypass grafting + mitral restrictive annuloplasty (2 sizes ring downsizing). Recurrent ischemic cardiomyopathy with chronic mitral regurgitation was defined by grade ≥ 2 at echocardiography.

Results: Hospital mortality was 4.9%; 17.7 ± 1.7 (standard error) months (range 1–55) survival was 95.5% ± 2.5%. Two-year Kaplan-Meier freedom from reintervention was 94.2% ± 4.2%; from rerevascularization, 87.5% ± 11.7%; from congestive heart failure, 83.8% ± 5.7%; from ischemic cardiomyopathy with chronic mitral regurgitation grade ≥ 2, 46.5% ± 11.2%. Recurrence of ischemic cardiomyopathy with chronic mitral regurgitation gave lower 2-year Kaplan-Meier freedom from death (P = .03) and lower 2-year freedom from congestive heart failure (P = .0001), reintervention (P = .034), and tricuspid insufficiency (P = .0001). Ischemic cardiomyopathy with chronic mitral regurgitation recurrence correlated with worsened New York Heart Association class (P = .0001), left ventricular ejection fraction (P = .024), pulmonary arterial pressures (P = .0001), left ventricular end-diastolic diameter (P = .004), left ventricular end-systolic diameter (P = .014), indexed left ventricular mass (P = .008), and coaptation depth (P = .0001). Independent predictors for recurrent ischemic cardiomyopathy with chronic mitral regurgitation were previous anterior + posterior myocardial infarction (odds ratio 3.70; confidence interval 2.93–5.41; P = .001), preoperative left ventricular end-diastolic diameter ≥ 70 mm (odds ratio 3.91; confidence interval 2.65–5.22; P = .001), and coaptation depth at discharge ≥ 0.5 cm (odds ratio 11.9; confidence interval 5.91–21.34; P = .0001). Preoperative left ventricular end-diastolic diameter ≥ 70 mm correlated with higher congestive heart failure (P = .002), recurrent ischemic cardiomyopathy with chronic mitral regurgitation (P = .0001), worsened New York Heart Association class (P = .0001), and higher diuretics (P = .0001). Coaptation depth < 0.5 cm at discharge accounted for better survival (P = .010), lower incidence of congestive heart failure (P = .0001), lower need for diuretics (P = .0001), and improved New York Heart Association class (P = .0001).

Conclusions: Failure of mitral restrictive annuloplasty is responsible for follow-up mortality and congestive heart failure and correlates with absence of cardiac reverse remodeling. Prognosis of patients having mitral restrictive annuloplasty for ischemic cardiomyopathy with chronic mitral regurgitation is good, as long as a low postoperative coaptation depth is achieved. Patients with significant left ventricular dilation should be considered for different surgical strategies.

Abbreviations and Acronyms AMI = acute myocardial infarction; CABG = coronary artery bypass grafting; CD = coaptation depth; CHF = congestive heart failure; CPB = cardiopulmonary bypass; ICMR = ischemic chronic mitral regurgitation; LAD = left atrial diameter; LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; LVMi = indexed left ventricular mass; mean {Delta}p = transmitral mean gradient; MRA = mitral restrictive annuloplasty; MV = mitral valve; NYHA = New York Heart Association; PAP = systolic pulmonary arterial pressure; TI = tricuspid insufficiency grading






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.